



Luxembourg, 17 Luxembourg 2025

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name:	ROVI PHARMA TECHNOLOGY RDI II
Project Number:	2020-0938
Country:	Spain
Project Description:	The project concerned the promoter's RDI activities in various drug delivery technologies and glycomics area, including preclinical development and clinical studies.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The project concerned investments in research and development that have been carried out in existing facilities without changing their already authorised scope. The project did not fall under any of Annexes of the Environmental Impact Assessment Directive – Directive 2014/52/EU amending Directive 2011/92/EU.

The project resulted in considerable social benefits resulting from new and improved drug delivery technology in psychiatry and oncology and the development and improvement of products in the glycomic area.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.

¹ The template is for ILs and FLs